Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

966
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
966
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

119
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
119
Genetic Lingo01:11

Genetic Lingo

109.2K
Overview
109.2K
Lipid Catabolism01:25

Lipid Catabolism

449
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
449
Pleiotropy01:33

Pleiotropy

41.9K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
41.9K
Lethal Alleles02:41

Lethal Alleles

17.2K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
17.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Atherosclerosis plus·2026
Same author

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal of atherosclerosis and thrombosis·2026
Same author

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Journal of atherosclerosis and thrombosis·2026
Same author

Sex Differences in the Diagnosis and Treatment of Japanese Patients With Familial Hypercholesterolemia: A Retrospective Cohort Study.

Journal of lipid and atherosclerosis·2026
Same author

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Journal of atherosclerosis and thrombosis·2026
Same author

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Internal medicine (Tokyo, Japan)·2026

Related Experiment Video

Updated: Nov 8, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.3K

Homozygous Familial Hypercholesterolemia.

Atsushi Nohara1, Hayato Tada2, Masatsune Ogura3

  • 1Department of Clinical Genetics, Ishikawa Prefectural Central Hospital.

Journal of Atherosclerosis and Thrombosis
|April 19, 2021
PubMed
Summary

Familial hypercholesterolemia (FH) is a genetic disorder affecting LDL clearance. Homozygous FH (HoFH) patients have severely impaired LDL receptor activity, necessitating distinct management strategies from heterozygous FH (HeFH).

Keywords:
Aortic Supra-valvular stenosisCutaneousFamily studyGenetic diagnosisHomozygous familial hypercholesterolemiaLipoprotein apheresisMTP inhibitorPCSK9 inhibitorTendon Xanthoma

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.9K

Related Experiment Videos

Last Updated: Nov 8, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.3K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.9K

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Familial hypercholesterolemia (FH) is an inherited disorder characterized by impaired low-density lipoprotein (LDL) clearance due to genetic mutations in the LDL receptor pathway.
  • Homozygous FH (HoFH) presents with significantly elevated LDL cholesterol (LDL-C) levels, approximately four times higher than normal, and a poorer prognosis compared to heterozygous FH (HeFH).
  • Recent genetic surveys suggest a higher prevalence of HoFH than previously estimated, ranging from 1 in 170,000 to 300,000.

Purpose of the Study:

  • To differentiate clinically between HoFH and HeFH, emphasizing the need for accurate diagnosis through family and genetic studies.
  • To review the critical clinical issues associated with HoFH, including early-onset cardiovascular complications.
  • To summarize current and potential therapeutic strategies for HoFH and discuss Japanese public healthcare insurance coverage.

Main Methods:

  • Review of existing literature on Familial Hypercholesterolemia, focusing on homozygous and heterozygous forms.
  • Analysis of genetic factors influencing LDL receptor activity and treatment response.
  • Examination of therapeutic interventions including lipoprotein apheresis, statins, PCSK9 inhibitors, and MTP inhibitors.
  • Summary of clinical management guidelines and insurance coverage in Japan.

Main Results:

  • HoFH patients exhibit severely impaired LDL receptor activity, leading to poor response to conventional therapies like statins.
  • Aggressive lipid-lowering therapy, initiated early, is crucial due to the risk of fatal cardiovascular events in the first decade of life.
  • Lipoprotein apheresis is a primary treatment, often requiring combination therapy to achieve LDL-C targets.
  • MTP inhibitors show efficacy independent of LDL receptor activity, offering a viable option for many HoFH cases.

Conclusions:

  • Accurate clinical distinction between HoFH and HeFH is essential for appropriate management.
  • Early and aggressive lipid-lowering strategies are vital for HoFH patients to mitigate severe cardiovascular risks.
  • Treatment selection for HoFH should consider the patient's residual LDL receptor activity, with MTP inhibitors representing a promising therapeutic avenue.